{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\n In a large‐scale analysis of long non‐coding RNAs (lncRNAs) across 15 human cancer types using nearly 7,000 clinical samples, ANKRD34C‐AS1 emerged as one of several lncRNAs that are aberrantly expressed in tumors compared to normal tissues. The study identified that a subset of lncRNAs—including ANKRD34C‐AS1—is consistently dysregulated in at least 10 cancer types, underscoring its potential conserved role in tumorigenesis. Moreover, the integration of expression data with somatic copy number alteration (SCNA) profiles revealed that such lncRNAs, likely including ANKRD34C‐AS1, harbor oncogenic potential and are associated with patient survival outcomes, thereby highlighting their prospective utility as novel clinical biomarkers and therapeutic targets."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": "\n "}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Ze-Lin Wang, Bin Li, Stephen R Piccolo, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Integrative analysis reveals clinical phenotypes and oncogenic potentials of long non-coding RNAs across 15 cancer types."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "Oncotarget (2016)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.18632/oncotarget.9037"}], "href": "https://doi.org/10.18632/oncotarget.9037"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "27147563"}], "href": "https://pubmed.ncbi.nlm.nih.gov/27147563"}]}]}]}